Pattern recognition of acute lymphoblastic leukemia (ALL) using computational deep learning
Leukemia is a cancer of blood-producing cells, including the bone marrow. Abnormal white
blood cells travel through blood vessels and multiply rapidly. Healthy cells in the body …
blood cells travel through blood vessels and multiply rapidly. Healthy cells in the body …
High-throughput methods for the analysis of transcription factors and chromatin modifications: Low input, single cell and spatial genomic technologies
M Salma, C Andrieu-Soler, V Deleuze… - Blood Cells, Molecules …, 2023 - Elsevier
Genome-wide analysis of transcription factors and epigenomic features is instrumental to
shed light on DNA-templated regulatory processes such as transcription, cellular …
shed light on DNA-templated regulatory processes such as transcription, cellular …
Applications of single‐cell omics for chimeric antigen receptor T cell therapy
Chimeric antigen receptor (CAR) T cell therapy is a promising cancer treatment modality.
The breakthroughs in CAR T cell therapy were, in part, possible with the help of cell analysis …
The breakthroughs in CAR T cell therapy were, in part, possible with the help of cell analysis …
Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency
S Aminov, O Giricz, DT Melnekoff… - The Journal of …, 2024 - Am Soc Clin Investig
While therapies targeting CD19 by antibodies, chimeric antigen receptor T cells (CAR-T),
and T cell engagers have improved the response rates in B cell malignancies, the …
and T cell engagers have improved the response rates in B cell malignancies, the …
[HTML][HTML] CAR-T cell therapy in B-cell acute lymphoblastic leukemia
Abstract Treatment of refractory and relapsed (R/R) B acute lymphoblastic leukemia (B-ALL)
is an unmet medical need in both children and adults. Studies carried out in the last two …
is an unmet medical need in both children and adults. Studies carried out in the last two …
Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy
ABSTRACT Introduction While CAR T-cell therapy has led to remarkable responses in
relapsed B-cell hematologic malignancies, only 50% of patients ultimately have a complete …
relapsed B-cell hematologic malignancies, only 50% of patients ultimately have a complete …
Harnessing the Transcriptional Signatures of CAR-T-Cells and Leukemia/Lymphoma Using Single-Cell Sequencing Technologies
YM Liao, SH Hsu, SS Chiou - International Journal of Molecular Sciences, 2024 - mdpi.com
Chimeric antigen receptor (CAR)-T-cell therapy has greatly improved outcomes for patients
with relapsed or refractory hematological malignancies. However, challenges such as …
with relapsed or refractory hematological malignancies. However, challenges such as …
This CAR won't start: predicting nonresponse in ALL
JA Webster, L Luznik - Blood Advances, 2023 - ashpublications.org
In this issue of Blood Advances, the article by Masih et al 1 presents a novel, multiomic
approach to predict which patients with relapsed/refractory B-cell acute lymphoblastic …
approach to predict which patients with relapsed/refractory B-cell acute lymphoblastic …
Unlocking the Complexity: Exploration of Acute Lymphoblastic Leukemia at the Single Cell Level
M Aertgeerts, S Meyers, S Demeyer, H Segers… - Molecular Diagnosis & …, 2024 - Springer
Acute lymphoblastic leukemia (ALL) is the most common cancer in children. ALL originates
from precursor lymphocytes that acquire multiple genomic changes over time, including …
from precursor lymphocytes that acquire multiple genomic changes over time, including …
CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia
S Sica - MEDITERRANEAN JOURNAL OF HEMATOLOGY AND …, 2024 - publicatt.unicatt.it
Abstract Treatment of refractory and relapsed (R/R) B acute lymphoblastic leukemia (B-ALL)
is an unmet medical need in both children and adults. Studies carried out in the last two …
is an unmet medical need in both children and adults. Studies carried out in the last two …